A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1323 participants.

Also called NCT03550443

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,323 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03550443
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03550443. Randomized; double masking; primary purpose treatment. Start 2018-05-30 (actual); primary completion 2022-11-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
Condition
Diabetic Kidney Disease
Intervention (Drug)
Bardoxolone methyl
Intervention (Drug)
Placebo
Lead sponsor
Kyowa Kirin Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct03550443
Content hash
a5de94799edfcf13d9351501a5d22cff07c2901676ff5520dfff49daf7703858